RNAi


Also found in: Dictionary, Medical, Acronyms, Wikipedia.

RNAi

[¦är¦en¦ā′ī]
(cell and molecular biology)
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
Mentioned in ?
References in periodicals archive ?
Inclisiran, the first cholesterol-lowering therapy in the RNAi therapeutics class, is an investigational therapy in Phase 3 clinical development to evaluate its ability to lower low-density lipoprotein cholesterol (also known as LDL-C) through twice-yearly dosing.
Various RNAi technologies are described, along with design and methods of manufacture of siRNA reagents.
RNAi (RNA interference) is reportedly a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today.
Currently there is no ideal experimental strategy for successful application of RNAi in the study of insect functional genes, probably due to the limited understating of the molecular basis of the RNAi mechanism in insects (Scott et al., 2013).
Read more about our RNAi Services http://www.altogenlabs.com/services/pre_clinical_research_services/therapeutic_sirna_development_shrna_mrna_reduction_gene_knockdown_stable_rnai
Today, the technology allows RNAi therapies to be administered intravenously, with the siRNA molecules encapsulated in tiny particles of lipids, which travel through the bloodstream to where they need to go.
"When we used RNAi to suppress expression of either the PBAN gene or the PBAN receptor gene, the ants produced less trail pheromone" than ants that did not receive the treatment, Vander Meer says.
The RNAi group used robotics to introduce small interfering RNAs (siRNAs) into human cells to individually turn off nearly 22,000 genes.
"We are excited about the progress being made by Tekmira scientists, who are leading the continued innovation of LNP delivery to enable the field of RNAi therapeutics.
Silence Therapeutics Plc.(AIM: SLN), a leading international RNAi therapeutics company HAS announces its unaudited preliminary results for the year ended 31 December 2011.
Mello, a UMass researcher who was co-recipient of the 2006 Nobel Prize in Medicine for his work on RNA interference, or RNAi, and it licensed technology from UMass.